CLINICAL TRIALS PROFILE FOR EPHEDRINE HYDROCHLORIDE

All Clinical Trials for EPHEDRINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00232817 ↗	Anesthesia and Postoperative Pain	Completed	Columbia University	Phase 4	2003-07-01	The purpose of this study is to compare post-operative pain after anesthesia with either isoflurane or propofol. Each group will be further randomized to recieve intranasal nicotine or placebo inorder to detect potetial pronociceptive action of isoflurane. The study is a randomized, prospective, double-blinded controlled trial. Eighty adult women undergoing uterine surgery will be recruited for this study. Enrollment in this study is limited to women, because our animal studies suggest that females have a greater hyperalgesic response to volatile anesthetics than do males. The patient will be given one of two standard anesthetics for their surgery: isoflurane or propofol. We are interested in these two anesthetics because we seek to see if there exists a difference in their effects on a patient's perception of pain, as has been shown to be the case in animal studies but has not yet been studied in humans. The primary outcome variable will be postoperative pain, as measured by a numerical analog pain score (VAS) at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 120, and 1440 minutes postoperatively. Secondary outcome measures will include morphine utilization via PCA and hemodynamics variables including heart rate, systolic BP, and diastolic BP, all of which will be measured at the same time points as the VAS score.
NCT00267332 ↗	Modafinil in Opioid Induced Sedation	Terminated	Sidney Kimmel Comprehensive Cancer Center	Phase 3	2006-01-01	- The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). - The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.
NCT00267332 ↗	Modafinil in Opioid Induced Sedation	Terminated	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 3	2006-01-01	- The primary objective of this study is to evaluate the efficacy of modafinil in the treatment of opioid induced sedation as measured by the Epworth Sleepiness Scale (ESS). - The secondary objective is to estimate the frequency and severity of toxicity associated with Modafinil (400mg) in patients with opioid induced sedation.
NCT00377975 ↗	"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat	Completed	Pennington Biomedical Research Center	Phase 2	2003-01-01	This study compares four treatments to see which one causes the most weight loss, fat loss, loss of abdominal fat and improvement in blood tests like cholesterol. The four treatments are: Placebo, Ephedrine plus caffeine, Pioglitazone, Combined pioglitazone and ephedrine plus caffeine
NCT00426842 ↗	A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride	Completed	James J. Peters Veterans Affairs Medical Center	Phase 2	2007-01-01	With upright postures, there is an immediate redistribution of blood to the dependent circulation; venous return and central venous filling pressure are reduced, resulting in diminution of cardiac output and blood pressure. These hemodynamic alterations stimulate the baroreceptor reflex, which is mediated via the central nervous system to increase peripheral sympathetic vasomotor tone, restoring blood pressure and cardiac output within seconds-to-minutes of the assumption of the upright position. Following SCI, individuals often experience the inability to adjust to postural changes due to disruption of central command of the baroreceptor reflex and reduction in efferent sympathetic neural pathways; consequently, orthostatic hypotension (OH) and symptoms of cerebral hypo-perfusion may ensue. OH is a well-documented phenomenon, which is characterized by a fall in systolic blood pressure of >20 mmHg or diastolic BP of > 10 mmHg within 3 minutes of assumption of an upright posture. As a consequence of OH, many individuals experience symptoms of cerebral hypo-perfusion which include lightheadedness, dizziness, blurry vision, fatigue, nausea, ringing in the ears, cognitive impairment and heart palpitations. Although several investigators have reported increased prevalence of OH during the acute phase of spinal cord injury (SCI), individuals with chronic injury also experience significant falls in blood pressure with seated upright postures. This investigation will examine the effects of an alpha-agonist, midodrine hydrochloride, during head-up tilt on systemic blood pressure, cerebral blood flow and cerebral oxygenation compared to placebo administration in persons with chronic SCI who demonstrate significant orthostatic hypotension during a 24-hour observation study. This is the first study to determine the dose response and efficacy of midodrine to improve orthostatic blood pressure and cerebral blood flow and oxygenation in the SCI population.
NCT00432991 ↗	Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section	Completed	New York Presbyterian Hospital	Phase 2	2007-02-01	The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.
NCT00432991 ↗	Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section	Completed	Weill Medical College of Cornell University	Phase 2	2007-02-01	The purpose of this research study is to investigate if the incidence of nausea and vomiting that subjects experience during and after a Cesarean section can be reduced by giving a shot of the drug ephedrine into the thigh muscle at the time of spinal anesthesia administration.

Clinical Trial Conditions for EPHEDRINE HYDROCHLORIDE

Condition Name

Condition Name for EPHEDRINE HYDROCHLORIDE
Intervention	Trials
Hypotension	28
Anesthesia	24
Cesarean Section	14
Spinal Anesthesia	13

Condition MeSH

Condition MeSH for EPHEDRINE HYDROCHLORIDE
Intervention	Trials
Hypotension	74
Pain, Postoperative	33
Pre-Eclampsia	11
Vomiting	10

Clinical Trial Locations for EPHEDRINE HYDROCHLORIDE

Trials by Country

Trials by Country for EPHEDRINE HYDROCHLORIDE
Location	Trials
United States	106
Egypt	101
Canada	27
Turkey	21
China	19

Trials by US State

Trials by US State for EPHEDRINE HYDROCHLORIDE
Location	Trials
New York	10
Illinois	7
California	6
Texas	5
North Carolina	5

Clinical Trial Progress for EPHEDRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for EPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	24
PHASE3	4
PHASE2	2

Clinical Trial Status

Clinical Trial Status for EPHEDRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	160
Recruiting	61
Not yet recruiting	37

Clinical Trial Sponsors for EPHEDRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for EPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Ain Shams University	19
Cairo University	18
Mansoura University	15

Sponsor Type

Sponsor Type for EPHEDRINE HYDROCHLORIDE
Sponsor	Trials
Other	344
Industry	13
U.S. Fed	1

EPHEDRINE HYDROCHLORIDE: Clinical Trials Update, Market Analysis, and 2025-2035 Projection

Last updated: May 2, 2026

What is the current clinical-trials signal for ephedrine hydrochloride?

Ephedrine hydrochloride’s clinical development footprint is dominated by long-standing or legacy indications and older trials, with limited evidence of active, late-stage contemporary registrational programs. Most recent public activity is concentrated in narrow, regulated-use contexts rather than global Phase 3 expansion.

Clinical-trials landscape (publicly observable pattern)

• Study type skew: pharmacology, perioperative dosing, and historical comparative studies rather than modern large-scale registrational programs.
• Regulatory posture: ephedrine hydrochloride is widely used under existing medical frameworks in multiple jurisdictions, which reduces incentives for new global Phase 3 trials unless formulations or new indications are pursued.
• Trial activity timing: the bulk of meaningful clinical evidence base is earlier than the past decade; current updates tend to be smaller studies, database entries, or targeted research rather than broad Phase 3 readouts.

Practical implication for R&D and investment

• Low probability of near-term “breakthrough” clinical readouts in mainstream indications without a formulation strategy (for example, controlled-release) or a repositioning strategy.
• Higher value in lifecycle and formulation/route work where regulatory pathways can leverage existing pharmacology and historical efficacy/safety.

What does the market look like for ephedrine hydrochloride today?

Ephedrine hydrochloride is a long-established, off-patent active pharmaceutical ingredient in many markets. Demand is primarily driven by:

1. Perioperative and emergency use (vasopressor support, anesthesia-related protocols).
2. Cold/flu and respiratory products in jurisdictions where regulatory frameworks permit ephedrine-containing formulations.
3. Regulated supply chain and diversion controls, which can constrain availability and pricing.

Market structure

• API and generics: ephedrine hydrochloride functions as a commodity-style API with multiple generic suppliers in many regions.
• Regulatory and supply friction: strict controls on ephedrine (and related precursors) drive procurement risk and can tighten supply windows.
• End-market concentration: hospital procurement systems and national distribution channels dominate volume for injectable and perioperative use.

Demand drivers

• Hospital utilization: anesthesia and emergency medicine protocols.
• Regulatory cyclicality: periodic tightening or loosening of national requirements can swing availability and pricing.
• Substitution pressure: in many markets, alternatives (including other sympathomimetics) can reduce incremental volume growth for ephedrine-specific formulations.

Cost and pricing dynamics

• Commodity behavior: margins are typically tied to raw material and compliance costs.
• Compliance cost pass-through: diversion-control requirements elevate non-recurring and ongoing overhead, affecting pricing stability.

What are the key risks to market growth?

1) Regulatory control and diversion restrictions

Ephedrine is subject to strict international and national control frameworks because it is a precursor for illicit synthesis. This increases administrative burden, limits sourcing flexibility, and can disrupt supply.

2) Substitution within perioperative and emergency settings

Clinicians and procurement teams can favor alternative vasopressor or bronchodilator options depending on local guidelines, procurement contracts, and safety profiles.

3) Formulation and lifecycle constraints

With the API’s long history and typical off-patent status, sustainable growth requires:

• differentiation through formulation (for example, controlled-release or injection line extensions),
• local regulatory approvals,
• or targeted use in specific care settings.

What is the 2025 to 2035 market projection for ephedrine hydrochloride?

A robust projection depends on region and formulation form factor (API vs finished dosage) and local regulation. With limited contemporary late-stage trial signals and commodity-style market dynamics, the most defensible projection is a low-to-moderate growth profile driven by continued hospital use and replacement of aging supply channels.

Base-case projection framework (directional)

• Global growth: modest, trackable to population aging, surgery volumes, and ongoing emergency and perioperative demand.
• Price trend: broadly range-bound with episodic swings tied to regulatory and supply disruptions.
• Volume vs value: volume growth lags value volatility because pricing reacts to supply constraints and compliance costs.

Projection ranges (global, directional)

Metric	2025	2028	2031	2035	Drivers
Market volume (units)	index 100	105-108	110-118	118-130	hospital utilization, substitution limits
Market value (USD terms)	index 100	103-112	107-125	115-145	supply friction, compliance cost pass-through
Net growth profile	low-to-moderate	steady	moderate variance	moderate variance	regulatory tightening cycles and procurement changes

Why clinical-trials updates do not materially change the forecast

Without a clear pattern of new late-stage outcomes or new indication expansion, the forecast is anchored to:

• existing medical utilization
• supply chain constraints
• generic competition
• substitution in key treatment contexts

Where the forecast can shift

The projection could move upward if a company succeeds in:

• securing specialized formulations with improved usability or stability,
• establishing exclusive supply contracts with regulated distribution,
• obtaining new local approvals for narrow, high-value indications.

What patent and regulatory context matters for strategy?

Ephedrine hydrochloride’s core molecule is not expected to be protected by new, molecule-wide patents in most jurisdictions; strategy typically depends on:

• formulation patents (release profiles, stability, dosing regimens),
• process patents (synthetic routes, impurity control),
• data exclusivity or local rights in specific markets for particular presentations.

Market participants typically compete on:

• supply reliability
• compliance capability
• finished product quality
• distribution access under controlled-substance style handling.

How should R&D teams position around clinical evidence and market reality?

Given the commodity-style baseline and constrained clinical novelty:

• Prioritize formulation and route improvements that reduce wastage, improve stability, or simplify hospital administration.
• Target jurisdiction-specific lifecycle strategies for injectable or perioperative formats.
• Build evidence around bioavailability, stability, and comparability rather than seeking entirely new clinical paradigms unless a specific, registerable niche exists.

Key Takeaways

• Ephedrine hydrochloride has limited contemporary late-stage trial momentum; the clinical evidence base is largely legacy and practical use-driven.
• The market behaves like a regulated, commodity-style API with demand anchored in hospital perioperative and emergency use.
• Growth is expected to be low-to-moderate from 2025 to 2035, with value more sensitive to supply and regulatory cycles than to new clinical breakthroughs.
• Competitive advantage will come from compliance execution, stable supply, and lifecycle/formulation differentiation, not new global indication expansion.

FAQs

1. Is ephedrine hydrochloride currently in late-stage clinical trials for new indications?
   Publicly observable development signals lean toward legacy and targeted studies rather than broad global Phase 3 registrational programs.

2. What drives hospital demand for ephedrine hydrochloride?
   Use in anesthesia-related protocols, emergency support, and perioperative care pathways where sympathomimetic effects are clinically applied.

3. How does generic competition affect pricing?
   Off-patent status and multi-supplier access in many markets typically produce range-bound pricing, with exceptions during supply or regulatory tightening events.

4. What is the largest market risk?
   Regulatory control and diversion-related compliance requirements that can tighten supply windows and increase operational friction.

5. What R&D strategy fits this molecule best?
   Lifecycle work focused on formulations, stability, route optimization, and local approvals aligned to hospital procurement needs.

---

References

[1] United Nations Office on Drugs and Crime (UNODC). Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances. UNODC.
[2] U.S. Drug Enforcement Administration (DEA). Chemical Control Program: Regulatory information and controls for listed chemicals. DEA.
[3] World Health Organization (WHO). WHO Model List of Essential Medicines. WHO.
[4] U.S. Food and Drug Administration (FDA). Controlled Substance and Drug Safety/Labeling information for sympathomimetics and relevant regulated substances. FDA.
[5] PubChem. Ephedrine Hydrochloride (CID/Drug Information). National Center for Biotechnology Information (NCBI).